Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02760797 · ClinicalTrials.gov registry record · Phase 1
A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT02760797 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 38 participants.
The verdict
NCT02760797, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
This is an open-label, multicenter study designed to assess the safety, pharmacokinetics, pharmacodynamics, and therapeutic activity of emactuzumab and RO7009789 administered in combination in participants with locally advanced or metastatic solid tumors that are not amenable to standard treatment. This study will be conducted in two parts: a dose-finding stage (Part I) and an expansion stage (Part II).
Interventions
- DRUG Emactuzumab
- DRUG RO7009789
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2016-05-09 |
| Est. Completion | 2018-04-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02760797
The ClinicalTrials.gov registry entry for NCT02760797 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Emactuzumab is the first listed.
NCT02760797 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02760797 about?
NCT02760797 is a clinical study titled "A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors". This is an open-label, multicenter study designed to assess the safety, pharmacokinetics, pharmacodynamics, and therapeutic activity of emactuzumab and RO7009789 administered in combination in participants with locally advanced or metastatic solid tumors that are not amenable to standard treatment. ...
What is the current status of trial NCT02760797?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2016-05-09. Estimated completion is 2018-04-06.
What interventions are being tested in trial NCT02760797?
The interventions under investigation include: Emactuzumab (DRUG), RO7009789 (DRUG).
Who is sponsoring clinical trial NCT02760797?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.